The Centers for Medicare and Medicaid Services plans to terminate four demonstration projects by the end of 2025, closing out ...
It's marketed as a generic option to name-brand mood meds, but it's been recalled for the same reason a competitor was just ...
The acquired portfolio consists of 13 ANDAs already approved by the Food and Drug Administration and one pending approval.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Geoffrey Joyce, PhD, director of ...